Breye Therapeutics is a clinical stage biopharmaceutical company developing first-in-class small molecule drugs suited for oral administration in patients with vascular eye diseases - Specifically, patients with Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD). The focus of the company is to develop orally administered products that are suited for earlier treatment intervention providing more effective and less burdensome treatment options for the very large and growing number of patients with DR and AMD - before they progress to advanced disease stages requiring needle-based therapies that are administered directly into the eye. The company is being lead by a strong team of ophthalmology experts and drug developers with a proven track record of successful product development leading to market entries.